Developability
Profiling
Finding Liabilities Early
AVS Bio’s workflow focuses on identifying potential liabilities at an early stage. Our developability assessment helps identify less well behaving antibodies, generating data that guides triaging and optimization strategies. To allow lead candidate benchmarking, we compare developability data to data obtained with a library of 100+ clinical antibodies, which we have analyzed in our in silico workflows and experimentally screened in our in vitro developability assays following recombinant production in CHO cells. This process makes it easier to determine clinical suitability based on relative ranking.
Resource:
In silico analysis
Developability
AVS Bio’s in silico developability profiling toolset includes sequence analysis, Fv model-based structure analysis, and Fv model-based surface analysis for lead antibody candidates to identify potential unfavorable properties, including (solvent-exposed) chemical liability motifs, aggregation prone regions, and charge properties. These in silico analyses, combined with benchmarking against our reference set of clinical antibodies, facilitate focused antibody de-risking (if required) to improve the antibody developability profile.
Humanness
AVS Bio’s platform evaluates antibody sequences for human similarity, providing a "humanness score" that reflects potential risk of immunogenicity. For sequences with a relative low humanness score, we offer tailored engineering solutions to potentially enhance its clinical suitability.
In vitro analysis
In vitro developability tools allow developers to study critical quality attributes such as production yield, polyreactivity, colloidal stability, melting temperature, self- and/or cross-interaction, solubility, and fragmentation. All lead candidate results are benchmarked against the reference set of clinical antibodies.
HPLC-based
AVS Bio uses state-of-the-art bio-inert high-performance liquid chromatography (HPLC) to perform analytical determination of biochemical and biophysical properties of antibodies. Analysis includes aggregation levels (SEC-HPLC), colloidal stability (SMAC-HPLC), cross interaction (CIC-HPLC), Asparagine (Asn) deamidation and isomerization (CIEX-HPLC), and Met/Trp oxidation (HIC-HPLC).
Plate-based
To complement its HPLC-based developability assay methods, AVS Bio offers plate-based assays to assess key biochemical and biophysical properties of antibodies. Polyreactivity against common biomolecules, including dsDNA, lipoproteins, LPS, and cardiolipin can be determined by ELISA. Alternatively, AVS Bio offers a label-free, high-throughput SPR-based method to screen for polyreactivity. In addition, developers can perform antibody melting temperature analysis using a plate-based thermal assay, providing valuable insights into stability.
